(Q37593086)

21 August 2017

1 reference

title

Dapagliflozin: where does it fit in the treatment of type 2 diabetes? (English)

1 reference

21 August 2017

0 references

Vincent C Woo

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

15

1 reference

21 August 2017

page(s)

2527-2535

1 reference

Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Health care and health status and outcomes for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Structure and function of hexose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Active sugar transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Long-term outcome of renal glucosuria type 0: the original patient and his natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Adaptation of intestinal nutrient transport in health and disease. Part I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903222281

10.1517/14656560903222281

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference